

SDZ 224-015

## Chemical Properties

CAS No. : 161511-45-1

Formula: C<sub>30</sub>H<sub>35</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>9</sub>


Molecular Weight: 652.52

Keep away from direct sunlight, Keep away from moisture

Storage:

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	SDZ 224-015 is an orally active inhibitor of interleukin-1 $\beta$ (IL-1 $\beta$ ) converting enzyme and caspase-1, exhibiting anti-COVID-19 and anti-inflammatory activity, and reducing carrageenan gum-induced paw edema in rats.
Targets(IC50)	Caspase,IL Receptor,Interleukin,SARS-CoV
In vitro	SDZ 224-015 dose-dependently inhibited the release of IL-1 $\beta$ from the human monocytic cell line THP-1, with an IC <sub>50</sub> of 0.24 $\mu$ M, without affecting the release of IL-6, TNF- $\alpha$ , or lactate dehydrogenase[2].
In vivo	SDZ 224-015 (0.3-300 micrograms kg <sup>-1</sup> ) potently reduced carrageenin-induced paw oedema, with an oral ED <sub>50</sub> of approximately 25 micrograms kg <sup>-1</sup> . SDZ 224-015 (0.2-5 mg kg <sup>-1</sup> , p.o.) displayed analgesic activity in the Randall-Selitto yeast-inflamed paw pressure test, significant at a dose of 1 mg kg <sup>-1</sup> , p.o[2].

## Solubility Information

Solubility	DMSO: 80 mg/mL (122.6 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Corn Oil: 3.3 mg/mL (5.06 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	1.5325 mL	7.6626 mL	15.3252 mL
5 mM	0.3065 mL	1.5325 mL	3.065 mL
10 mM	0.1533 mL	0.7663 mL	1.5325 mL
50 mM	0.0307 mL	0.1533 mL	0.3065 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Martin A Redhead, et al. Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. *Sci Rep.* 2021 Jun 24;11(1):13208.

P R Elford, et al. Reduction of inflammation and pyrexia in the rat by oral administration of SDZ 224-015, an inhibitor of the interleukin-1 beta converting enzyme. *Br J Pharmacol.* 1995 Jun;115(4):601-6.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481